PF-CBP1

Research use only, not for human use.

A potent, highly selective CBP/p300 bromodomains inhibitor with IC50 of 125 nM and 363 nM, respectively.

A potent, highly selective CBP/p300 bromodomains inhibitor with IC50 of 125 nM and 363 nM, respectively; displays >100-fold selectivity for the bromodomain of CBP over those of BRD4 and a panel of other proteins; reduces the expression of inflammatory cytokines by LPS-stimulated primary macrophages, also suppresses the expression of RGS4 in primary cortical neurons.

PF-CBP1 modulates key inflammatory genes in primary macrophages. PF-CBP1 downregulates RGS4 in neurons, a target linked to Parkinson's disease. PF-CBP1 is 139-fold selective over BRD4 in the biochemical assays and >105-fold selective by ITC.F-CBP1 is also a potent inhibitor of EP300 (a result observed for other CBP inhibitors.

——

PF CBP1

Chromatin/Epigenetic

Bromodomain

CREB

——

——

1962928-21-7

488.6

C29H36N4O3

>98% (HPLC)

DMSO: 100 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

CCCOC1=CC=C(C=C1)CCC2=NC3=C(N2CCN4CCOCC4)C=CC(=C3)C5=C(ON=C5C)C

4-(2-(5-(3,5-dimethylisoxazol-4-yl)-2-(4-propoxyphenethyl)-1H-benzo[d]imidazol-1-yl)ethyl)morpholine

(-20℃)

With Ice Pack

≥ 2 years